[1]刘莉莉.玻璃体腔内注药联合口服药物治疗后极部弓形虫脉络膜视网膜炎1例报道[J].医学信息,2021,(20):185-187.[doi:10.3969/j.issn.1006-1959.2021.20.051]
点击复制

玻璃体腔内注药联合口服药物治疗后极部弓形虫脉络膜视网膜炎1例报道()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2021年20期
页码:
185-187
栏目:
出版日期:
2021-10-20

文章信息/Info

文章编号:
1006-1959(2021)20-0185-03
作者:
刘莉莉
广西医科大学第四附属医院/柳州市工人医院眼科,广西 柳州 545005
关键词:
玻璃体腔弓形虫脉络膜视网膜炎甲氧苄啶磺胺甲恶唑克林霉素
分类号:
R774;R531.8
DOI:
10.3969/j.issn.1006-1959.2021.20.051
文献标志码:
B

参考文献/References:

[1]Egorov AI,Converse R,Griffin SM,et al.Environmental risk factors for Toxoplasma gondii infections and the impact of latent infections on allostatic load in residents of Central North Carolina[J].BMC Infect Dis,2018,18(1):421.[2]Kedhar SR.Research in Uveitis and Ocular Inflammation, 2011 to 2012[J].Asia Pac J Ophthalmol (Phila),2013,2(3):187-198.[3]Bonfioli AA,Orefice F.Toxoplasmosis[J].Lancet,2009,20(3):129-141.[4]Aleixo AL,Curi AL,Benchimol EI,et al.Toxoplasmic Retinochoroiditis: Clinical Characteristics and Visual Outcome in a Prospective Study[J]. PLoS Negl Trop Dis,2016,10(5):e0004685.[5]Mathis T,Beccat S,Seve P,et al.Comparison of immunoblotting (IgA and IgG) and the Goldmann-Witmer coefficient for diagnosis of ocular toxoplasmosis in immunocompetent patients[J].Br J Ophthalmol,2018,102(10):1454-1458.[6]Commodaro AG,Belfort RN,Rizzo LV,et al.Ocular toxoplasmosis: an update and review of the literature[J].Mem Inst Oswaldo Cruz,2009,104(2):345-350.[7]Lasave AF,Diaz-Llopis M,Muccioli C,et al.Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months[J]. Ophthalmology,2010,117(9):1831-1838.[8]Holland GN.Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease[J].Am J Ophthalmol,2003,136(6):973-988.[9]Wakefield D,Cunningham ET,Pavesio C,et al.Controversies in ocular toxoplasmosis[J]. Ocul Immunol Inflamm,2011,19(1):2-9.[10]Holland GN.Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management[J]. Am J Ophthalmol,2004,137(1):1-17.[11]Stanford MR,See SE,Jones LV,et al.Antibiotics for toxoplasmic retinochoroiditis[J].Ophthalmol,2003,110(5):926-932.[12]Koloren Z,Dubey JP.A review of toxoplasmosis in humans and animals in Turkey[J].Parasitology,2019,147(1):12-28.[13]Chiang WS.Exacerbation of recurrent acquired ocular toxoplasmosis after an initial response to treatment:a case report[J]. International Journal of Ophthalmology,2011,11(10):1687-1691. [14]苗晓凯.乙酰螺旋霉素联合阿奇霉素治疗孕期弓形虫感染的临床效果[J].中国合理用药探索,2018,15(6):13-15.[15]王卫群.阿奇霉素,青蒿琥酯,乙酰螺旋霉素及配伍用药体内外抗弓形虫作用的实验研究[D].南宁:广西医科大学,2009.[16]Dunay IR,Gajurel K,Dhakal R,et al.Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice[J].Clin Microbiol Rev,2018,31(4):e00057.[17]Pradhan E,Bhandari S,Gilbert RE,et al.Antibiotics versus no treatment for toxoplasma retinochoroiditis[J].Cochrane Database Syst Rev,2016(5):CD002218.[18]曹绪胜,纪海霞,张永鹏,等.全身使用糖皮质激素继发中心性浆液性脉络膜视网膜病变的临床特征[J].眼科,2020,29(3):193-197.[19]Baharivand N,Mahdavifard A,Fouladi RF.Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial[J].Int Ophthalmol,2013,33(1):39-46.[20]武静. OCT联合眼底荧光血管造影在中心性浆液性视网膜脉络膜炎诊断中的应用[J]. 现代医用影像学,2018,27(6):2061,2098.[21]成拾明,张茂菊,阮坤炜,等.眼弓形虫病临床特征及治疗预后分析[J].中华眼底病杂志,2020,36(9):680-684.

更新日期/Last Update: 1900-01-01